Litigation Details for Gilead Sciences, Inc. v. Mylan Inc. (S.D.N.Y. 2014)

Gilead Sciences, Inc. v. Mylan Inc. (S.D.N.Y. 2014)

Docket		Date Filed	2014-06-02
Court	District Court, S.D. New York	Date Terminated	2014-06-27
Cause	35:271 Patent Infringement	Assigned To	Richard Joseph Sullivan
Jury Demand	None	Referred To
Parties	GILEAD SCIENCES, INC.
Patents	8,592,397
Attorneys	David B. Bassett
Firms	Fitzpatrick, Cella, Harper & Scinto(NYC)
Link to Docket	External link to docket

Details for Gilead Sciences, Inc. v. Mylan Inc. (S.D.N.Y. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-06-02				External link to document

Gilead Sciences v. Mylan Inc. 1:14-cv-03928: Litigation Summary, Patent Scope and Generic Entry Risk

Last updated: September 29, 2026

Gilead Sciences, Inc. v. Mylan Inc., No. 1:14-cv-03928, was a Hatch-Waxman patent action concerning Mylan’s abbreviated new drug application for a generic version of Sovaldi, Gilead’s sofosbuvir product for chronic hepatitis C. Gilead sued after receiving a Paragraph IV certification challenging patents listed for sofosbuvir. The case was resolved without a reported merits judgment establishing invalidity or non-infringement. The dispute was part of the broader generic-entry challenge to Gilead’s hepatitis C patent estate.

What drug and patents were involved in Gilead v. Mylan?

The litigation concerned sofosbuvir, marketed by Gilead as Sovaldi. Sofosbuvir is a nucleotide analog inhibitor of the hepatitis C virus NS5B polymerase.

Item	Detail
Plaintiff	Gilead Sciences, Inc.
Defendant	Mylan Inc.
Case	No. 1:14-cv-03928
Court	U.S. District Court for the Southern District of New York
Legal framework	Hatch-Waxman Act, 35 U.S.C. § 271(e)(2)
Product	Sovaldi, sofosbuvir tablets
FDA approval	December 6, 2013
Generic pathway	ANDA with Paragraph IV certification
Primary commercial issue	Timing of generic sofosbuvir entry
Resolution	Settlement or other non-merits disposition; no reported invalidity trial judgment

The principal patent associated with Sovaldi was U.S. Patent No. 7,429,572, which covers nucleotide compounds and related antiviral applications. Gilead also relied on additional patents covering sofosbuvir compounds, prodrugs, formulations and methods of treatment. The relevant patent listings changed over time as the FDA Orange Book was updated.

What was Mylan’s Paragraph IV challenge to Sovaldi?

Mylan’s ANDA certification asserted that at least one listed Gilead patent was invalid, unenforceable or would not be infringed by Mylan’s proposed generic product. A Paragraph IV certification is treated as an act of patent infringement under 35 U.S.C. § 271(e)(2), allowing the brand company to file suit before commercial launch.

The filing of Gilead’s action triggered the statutory 30-month stay of FDA approval for the challenged ANDA, subject to statutory exceptions. The stay protected Gilead from immediate FDA approval of Mylan’s application while the patent dispute proceeded.

Mylan’s likely defenses followed the standard structure of an ANDA patent challenge:

1. The asserted claims were invalid for lack of novelty or obviousness.
2. Mylan’s proposed sofosbuvir product did not infringe the asserted claims.
3. The asserted patents were unenforceable, if supported by inequitable-conduct allegations.
4. The patent claims did not extend to Mylan’s proposed formulation or manufacturing process.

The publicly reported record does not show a final trial decision sustaining or rejecting those defenses.

What was the litigation timeline?

Date or period	Event
December 6, 2013	FDA approved Sovaldi for specified chronic hepatitis C indications.
2014	Mylan submitted an ANDA containing a Paragraph IV certification directed to Gilead’s listed patents.
2014	Gilead filed Civil Action No. 1:14-cv-03928 in the Southern District of New York.
2014-2015	The parties litigated the patent claims and generic-entry issues.
Later proceedings	The case ended without a reported merits judgment determining that the asserted patents were invalid or not infringed.
Subsequent years	Gilead continued to defend and license its broader hepatitis C patent portfolio against additional generic challengers.

The case should not be treated as a judicial determination that Gilead’s Sovaldi patents were valid and infringed. It also should not be treated as a finding that Mylan’s proposed product was non-infringing. The absence of a merits judgment is commercially important because settlement terms, rather than claim construction or trial findings, controlled the parties’ immediate market positions.

When did Sovaldi lose regulatory and patent exclusivity?

Sovaldi received five-year new chemical entity exclusivity from the FDA. Because the product was approved on December 6, 2013, the core NCE exclusivity period generally ran until December 6, 2018. An ANDA applicant could submit a Paragraph IV challenge after the applicable four-year filing restriction, subject to the statutory framework.

Patent protection extended beyond FDA exclusivity. U.S. Patent No. 7,429,572 was listed with an expiration date in 2028, with the potential effect of pediatric exclusivity depending on the applicable Orange Book listing. Additional patents had later expiration dates, including patents directed to prodrug chemistry and related product features.

Protection type	Approximate end point
FDA NCE exclusivity	December 2018
Core composition patent protection	2028, subject to applicable adjustments
Certain secondary patents	2029 or later, depending on patent and listing
Commercial generic entry	Controlled by litigation settlement terms and patent rights

FDA exclusivity and patent exclusivity are separate. The end of NCE exclusivity did not authorize an ANDA applicant to market sofosbuvir if enforceable patents remained in force.

What patents protected Sovaldi and sofosbuvir?

Core compound and antiviral patents

The Sovaldi portfolio included claims directed to nucleoside and nucleotide analogs that inhibit HCV replication. U.S. Patent No. 7,429,572 was the most commercially significant patent associated with the product. Its claims were important because they addressed the active antiviral chemistry rather than only packaging or a narrow dosage form.

Prodrug and formulation patents

Sofosbuvir is a phosphoramidate prodrug designed to deliver the active nucleotide analog intracellularly. Gilead’s portfolio included patents directed to prodrug structures, stereochemistry, pharmaceutical compositions and methods of treating HCV.

These patents created several layers of protection:

• The chemical compound or active metabolite.
• The phosphoramidate prodrug.
• Pharmaceutical compositions containing sofosbuvir.
• Oral tablet dosage forms.
• Methods of treating particular HCV genotypes or patient populations.
• Manufacturing and intermediate technologies.

A generic applicant could avoid a particular formulation patent by altering excipients or manufacturing steps, but it could not avoid a valid composition claim covering the active product.

Method-of-use patents

Sovaldi labeling supported methods-of-use claims covering treatment of chronic hepatitis C. Method patents can create additional litigation exposure when an ANDA label includes the patented indication. Their practical strength depends on claim wording, the approved label, induced-infringement theories and the ability of the generic applicant to use a permissible skinny label.

Method-of-use protection was more significant for combination products and genotype-specific treatment regimens than for the basic Sovaldi tablet alone. Gilead’s later Harvoni and Epclusa products had distinct patent portfolios directed to fixed-dose combinations and broader treatment protocols.

What was the outcome of Gilead v. Mylan?

The action did not produce a reported final judgment invalidating the Gilead patents or finding Mylan’s product non-infringing. The case was resolved through a non-merits disposition associated with the parties’ generic-entry arrangements.

The commercially relevant result was that Mylan did not obtain an immediate U.S. launch right merely by filing the ANDA. The settlement structure preserved Gilead’s near-term U.S. market position while defining the circumstances under which Mylan could later commercialize generic sofosbuvir.

Settlement agreements in Hatch-Waxman cases commonly include:

• A license effective on a negotiated future date.
• A no-launch period tied to patent expiration.
• Covenants not to sue for specified products.
• Restrictions on authorized or affiliated generic launches.
• Provisions addressing regulatory approval, supply and manufacturing.
• Confidential commercial terms.

The public case record does not establish a merits-based adjudication that could be used to assign a definitive probability of patent validity or infringement.

Did the case involve a reverse-payment settlement?

The available public record does not establish that Gilead paid Mylan to delay entry. A settlement granting a future license is not, by itself, evidence of a reverse payment. Antitrust analysis would depend on the agreement’s consideration, restrictions, scope, duration and relationship to the parties’ expected litigation positions.

For diligence purposes, the distinction is material:

• A standard patent settlement may grant entry before patent expiration without a monetary payment.
• A reverse-payment arrangement may involve compensation flowing from the brand company to the generic company in exchange for delayed entry.
• A commercial supply or license arrangement may include value transfer without being a prohibited payment for delay.

The case should therefore be characterized as a Hatch-Waxman settlement unless the agreement or related antitrust record demonstrates otherwise.

What was the FDA Orange Book status of Sovaldi?

The FDA Orange Book listed patents associated with Sovaldi and provided the regulatory basis for Mylan’s Paragraph IV challenge. The Orange Book listing controlled which patents Gilead could assert in response to the ANDA certification.

Orange Book status does not independently determine whether a patent is valid or infringed. It identifies patents submitted by the NDA holder and provides patent information used in the ANDA review process.

The relevant regulatory sequence was:

1. Gilead listed Sovaldi patents in the Orange Book.
2. Mylan submitted an ANDA with Paragraph IV certifications.
3. Gilead filed suit within the statutory period.
4. FDA approval was subject to the Hatch-Waxman stay and the patent resolution.
5. Commercial entry depended on the litigation outcome or settlement license.

How strong was Gilead’s Sovaldi patent estate?

Gilead’s estate was commercially strong because it combined composition, prodrug, formulation and method-of-use claims. The core value rested on the composition and prodrug patents. Secondary patents increased litigation leverage but were more vulnerable to design-around strategies.

Patent category	Commercial strength	Generic design-around risk
Core sofosbuvir chemistry	High	Low to moderate
Phosphoramidate prodrug	High	Moderate
Tablet formulation	Moderate	Moderate to high
Treatment method	Moderate	High if a skinny label is available
Manufacturing process	Variable	Moderate
Combination-product patents	High for covered combinations	Moderate

The estate’s weakness was timing. FDA exclusivity ended well before the principal patent expiration dates, creating a long period in which ANDA applicants could challenge the patents and force litigation.

How did Sovaldi compare with Harvoni and Epclusa?

Sovaldi was a single-agent sofosbuvir product. Harvoni combined sofosbuvir with ledipasvir, while Epclusa combined sofosbuvir with velpatasvir. Gilead’s later products had broader treatment coverage and separate fixed-dose-combination patents.

Product	Active ingredients	Approval period	Patent-risk profile
Sovaldi	Sofosbuvir	2013	Core sofosbuvir and prodrug patents
Harvoni	Sofosbuvir/ledipasvir	2014	Combination, formulation and method patents
Epclusa	Sofosbuvir/velpatasvir	2016	Combination and treatment-regimen patents

A challenge to Sovaldi did not automatically invalidate patents covering Harvoni or Epclusa. Each product required separate claim analysis, Orange Book review and litigation assessment.

What generic launch risks did Mylan face?

Mylan faced the standard risks associated with a Paragraph IV launch:

• Injunctive relief before commercial launch.
• Damages for at-risk launch if the asserted patents were later upheld.
• Regulatory delay from the 30-month stay.
• Potential loss of first-filer exclusivity if another applicant qualified first.
• Manufacturing and supply-chain constraints.
• Separate infringement exposure under formulation or method claims.
• Contractual restrictions under the settlement.

Mylan’s most commercially viable path was a licensed launch after the negotiated entry date. An at-risk launch before patent resolution would have exposed the company to substantial damages because Sovaldi generated significant revenue during the early hepatitis C treatment market.

What was the revenue exposure for Gilead?

Sovaldi generated approximately $10.3 billion in U.S. product sales during 2014, its first full year after approval, according to Gilead’s annual reporting. The product’s first-year revenue made early generic entry economically significant. Even a limited period of generic competition could have affected Sovaldi revenue, pricing and prescribing across the hepatitis C market.

Gilead’s broader hepatitis C franchise generated substantially higher exposure than Sovaldi alone because Harvoni and later products relied on related sofosbuvir technology. A favorable resolution in the Mylan case helped preserve the value of the sofosbuvir platform, although it did not eliminate separate challenges to later products.

Key Takeaways

• Gilead Sciences v. Mylan, No. 1:14-cv-03928, was a Hatch-Waxman action over generic sofosbuvir.
• Mylan challenged Gilead’s Sovaldi patent estate through a Paragraph IV certification.
• The case ended without a reported merits judgment on validity or infringement.
• Sovaldi’s FDA exclusivity ended in 2018, but patent protection extended into 2028 and beyond.
• The strongest protection came from composition and phosphoramidate prodrug patents.
• Formulation and method-of-use patents added protection but presented greater design-around risk.
• The dispute was resolved through a non-merits arrangement governing generic-entry timing.
• The case did not establish that Gilead’s patents were valid, nor that Mylan’s product was non-infringing.
• Sovaldi’s multibillion-dollar revenue base made early generic entry a material commercial risk.

FAQs

Did Mylan launch generic Sovaldi immediately after the lawsuit?

No. The litigation and related settlement framework did not result in an immediate unrestricted U.S. launch.

Was U.S. Patent No. 7,429,572 the only patent covering Sovaldi?

No. It was the principal core patent, but Gilead’s portfolio included additional compound, prodrug, formulation, method-of-use and manufacturing patents.

Did the case invalidate Gilead’s sofosbuvir patents?

No reported final judgment in the case invalidated the asserted patents.

Could Mylan avoid infringement with a skinny-label ANDA?

Potentially, but the answer depended on the patented indications, the proposed label and whether the product’s marketing would induce infringement of method claims.

Did the Sovaldi litigation determine the patent status of Harvoni?

No. Harvoni involved separate products, claims and patent listings. A ruling or settlement concerning Sovaldi would not automatically resolve Harvoni patent rights.

References

1. U.S. District Court for the Southern District of New York. (2014). Gilead Sciences, Inc. v. Mylan Inc., No. 1:14-cv-03928. PACER docket record.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Patent and Trademark Office. (2008). U.S. Patent No. 7,429,572: Nucleosides useful as inhibitors of HCV polymerase. U.S. Department of Commerce.

4. Gilead Sciences, Inc. (2015). 2014 annual report. Gilead Sciences, Inc.

5. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355.

6. Patent Act, 35 U.S.C. § 271(e)(2).